PRDM16 suppresses HIF-targeted gene expression in kidney cancer

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Renal cell carcinoma (RCC) exhibits extensive epigenetic gene silencing of the transcription factor PRDM16.
• PRDM16 plays a crucial role in cellular differentiation and tumor suppression.
• Semaphorin 5B (SEMA5B), a hypoxia-inducible factor (HIF) target gene, is highly expressed in RCC and promotes tumor growth.

Purpose of the Study:

• To investigate the role of PRDM16 in epigenetic regulation within renal cancer.
• To elucidate the mechanism by which PRDM16 suppresses tumor growth in RCC.
• To identify novel therapeutic targets for kidney cancer treatment.

Main Methods:

• Transcriptomic analysis (RNA-seq) to assess gene expression changes.
• In vivo studies using RCC cells to evaluate tumor growth suppression.
• Co-immunoprecipitation assays to determine protein-protein interactions.
• Functional studies with PRDM16 mutants to assess the role of corepressor binding.

Main Results:

• Restoration of PRDM16 in RCC cells significantly suppressed in vivo tumor growth.
• PRDM16 exhibited a predominantly repressive effect on the RCC transcriptome, including the suppression of SEMA5B.
• PRDM16's tumor suppressive function and SEMA5B repression were dependent on its physical interaction with C-terminal binding proteins (CtBP1/2).
• A PRDM16 mutant unable to bind CtBPs failed to suppress SEMA5B expression and tumor growth.

Conclusions:

• PRDM16 acts as a tumor suppressor in renal cancer through epigenetic mechanisms.
• PRDM16 represses HIF target genes, such as SEMA5B, by interacting with CtBP corepressors.
• This study uncovers a novel epigenetic mechanism driving gene amplification in kidney cancer and highlights PRDM16 as a potential therapeutic target.